• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Thera (NQ: AXSM )

    73.92 +0.16 (+0.22%)
    Streaming Delayed Price Updated: 12:19 PM EDT, May 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 137,275
    Open 74.03
    Bid (Size) 73.89 (4)
    Ask (Size) 74.02 (1)
    Prev. Close 73.76
    Today's Range 73.28 - 75.51
    52wk Range 55.02 - 98.40
    Shares Outstanding 47,190,970
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Axsome Therapeutics Recognizes May as Mental Health Awareness Month
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Performance

    YTD
    -4.07%
    -4.07%
    1 Month
    -3.99%
    -3.99%
    3 Month
    -19.57%
    -19.57%
    6 Month
    +18.69%
    +18.69%
    1 Year
    +4.45%
    +4.45%

    More News

    Read More
    3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
    Via InvestorPlace
    Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
    Via Benzinga
    Analyst Ratings For Axsome Therapeutics
    Via Benzinga
    2 Under-the-Radar Growth Stocks to Consider
    Via The Motley Fool
    What Analysts Are Saying About Axsome Therapeutics Stock
    Via Benzinga
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
    Via The Motley Fool
    Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    What Analysts Are Saying About Axsome Therapeutics Stock
    Via Benzinga
    Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
    Via InvestorPlace
    Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
    Via Benzinga
    Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
    Via The Motley Fool
    Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.